HC Wainwright Has Negative Forecast for DNTH FY2024 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Research analysts at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Dianthus Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($3.06) per share for the year, down from their previous estimate of ($2.33). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2024 earnings at ($1.14) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.29) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.47) EPS, FY2026 earnings at ($4.89) EPS, FY2027 earnings at ($4.61) EPS and FY2028 earnings at ($3.94) EPS.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million.

Other equities research analysts also recently issued reports about the stock. Wedbush cut their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Robert W. Baird started coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 price target for the company. Oppenheimer increased their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Finally, Raymond James lifted their price target on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $25.49 on Thursday. The business has a fifty day simple moving average of $27.65 and a two-hundred day simple moving average of $26.63. Dianthus Therapeutics has a 1 year low of $6.58 and a 1 year high of $33.77. The company has a market capitalization of $754.43 million, a price-to-earnings ratio of -10.20 and a beta of 1.84.

Institutional Trading of Dianthus Therapeutics

Several large investors have recently made changes to their positions in the company. Bain Capital Life Sciences Investors LLC acquired a new stake in shares of Dianthus Therapeutics in the 1st quarter worth about $89,761,000. RA Capital Management L.P. purchased a new position in Dianthus Therapeutics during the 1st quarter worth $69,990,000. Great Point Partners LLC grew its position in Dianthus Therapeutics by 21.3% in the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after purchasing an additional 132,929 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after acquiring an additional 384,182 shares in the last quarter. Finally, Braidwell LP increased its position in shares of Dianthus Therapeutics by 34.6% during the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after acquiring an additional 126,836 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.